> file caplus

COST IN U.S. DOLLARS SINCE FILE
TOTAL
ENTRY
SESSION
FULL ESTIMATED COST 0.15
0.15

FILE 'CAPLUS' ENTERED AT 07:56:56 ON 17 NOV 1998
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.


FILE COVERS 1967 - 17 Nov 1998 VOL 129 ISS 21
FILE LAST UPDATED: 17 Nov 1998 (981117/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

This file supports REG1stRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

=> s liposome?(5a)(polylact? or polyglycol? or polyvinyl?)

29880 LIPOSOME?
3731 POLYLACT?
4786 POLYGLYCOL?
68551 POLYVINYL?
L1 36 LIPOSOME?(5A)(POLYLACT? OR POLYGLYCOL? OR POLYVINYL?)

=> d 1-36

L1 ANSWER 1 OF 36 CAPLUS COPYRIGHT 1998 ACS
AN 1998:268337 CAPLUS
DN 128:326510
TI Compound-loaded liposomes and methods for their preparation
IN Kirpotin, Dmitri

PA Kirpotin, Dmitri, USA
SO PCT Int. Appl., 39 pp.
CODEN: PIXXD2
PI WO 9817256 A1 19980430
DS W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT,
RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FI, FR, GA, GB,
GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG
AI WO 97-US18929 19971021
PRAI US 96-28931 19961022
DT Patent
LA English

L1 ANSWER 2 OF 36 CAPLUS COPYRIGHT 1998 ACS
AN 1998:251033 CAPLUS
DN 128:326494
TI Fusogenic liposome composition and method
IN Martin, Francis J.; Zalipsky, Samuel
PA Sequus Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 61 pp.
CODEN: PIXXD2
PI WO 9816202 A2 19980423
DS W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR,
KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG,
UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FI, FR, GA, GB,
GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG
AI WO 97-US18838 19971010
PRAI US 96-28269 19961011
DT Patent
LA English

L1 ANSWER 3 OF 36 CAPLUS COPYRIGHT 1998 ACS
AN 1998:251032 CAPLUS
DN 128:312914
TI Therapeutic liposome composition and method
IN Zalipsky, Samuel; Martin, Francis J.; Huang, Shi Kun
PA Sequus Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 42 pp.
CODEN: PIXXD2
PI WO 9816201 A1 19980423
DS W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,

DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR,
KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG,
UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FI, FR, GA, GB,
GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG
AI WO 97-US18813 19971009
PRAI US 96-27923 19961011
DT Patent
LA English

L1 ANSWER 4 OF 36 CAPLUS COPYRIGHT 1998 ACS
AN 1998:230853 CAPLUS
DN 129:8498
TI Physical stability of size controlled small unilamellar liposomes
coated with a modified poly(vinyl alcohol)
AU Takeuchi, Hirofumi; Yamamoto, Hiromitsu; Toyoda, Toshitada; Toyobuku, Hidekazu; Hino, Tomoaki; Kawashima, Yoshiaki
CS Gifu Pharmaceutical University, Gifu, 502, Japan
SO Int. J. Pharm. (1998), 164(1-2), 103-111
CODEN: IJPHDE; ISSN: 0378-5173
PB Elsevier Science B.V.
DT Journal
LA English

L1 ANSWER 5 OF 36 CAPLUS COPYRIGHT 1998 ACS
AN 1998:205175 CAPLUS
DN 128:318554
TI Stabilization of DMPC-liposomes by neutral polymers
AU Grohmann, Ferenc Levente; Csempesz, Ferenc
CS Eotvos Lorand Tudomanyegyetem Kolloidkemiai Tanszek, Budapest, 1518,
Hung.
SO Magy. Kem. Foly. (1998), 104(2), 53-59
CODEN: MGKFA3; ISSN: 0025-0155
PB Magyar Kemikusok Egyesulete
DT Journal
LA Hungarian

L1 ANSWER 6 OF 36 CAPLUS COPYRIGHT 1998 ACS
AN 1998:147189 CAPLUS
DN 128:208914
TI Liposomes containing a cisplatin compound
IN Abra, Robert M.; Reis, Karen
PA Sequus Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 39 pp.
CODEN: PIXXD2
PI WO 9807409 A1 19980226
DS W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ,

LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL,
PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ,
VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FI, FR, GA, GB,
GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG
AI WO 97-US14541 19970819
PRAI US 96-24350 19960823
DT Patent
LA English

L1 ANSWER 7 OF 36 CAPLUS COPYRIGHT 1998 ACS
AN 1997:609040 CAPLUS
DN 127:263313
TI Macromolecules in ordered media: 7. Influence of ionic strength and
bilayer composition on the association of polyelectrolytes to mixed
liposomes
AU Porcar, Iolanda; Garcia, Rosa; Gomez, Clara; Campos, Agustin; Abad,
Concepcion
CS Department de Quimica Fisica and Institut de Ciencies de Materials
(ICMUV), Universitat de Valencia, Valencia, 46100, Spain
SO Polymer (1997), 38(20), 5107-5113
CODEN: POLMAG; ISSN: 0032-3861
PB Elsevier
DT Journal
LA English

L1 ANSWER 8 OF 36 CAPLUS COPYRIGHT 1998 ACS
AN 1997:515155 CAPLUS
DN 127:201703
TI Macromolecules in ordered media. Part 6. Effect of the phospholipidic bilayer composition on poly (2-vinylpyridine)-liposome association
AU Porcar, Iolanda; Garcia, Rosa; Soria, Vicente; Abad, Concepcion;
Campos, Agustin
CS Departament Quimica Fisica, Universitat Valencia, Valencia, Spain
SO Macromol. Symp. (1997), 119, 241-252
CODEN: MSYMEC; ISSN: 1022-1360
PB Huethig & Wepf
DT Journal
LA English

L1 ANSWER 9 OF 36 CAPLUS COPYRIGHT 1998 ACS
AN 1997:429986 CAPLUS
DN 127:136284
TI Macromolecules in ordered media. 5. Poly(4-vinyl pyridine)-liposome
association induced by electrostatic interactions
AU Porcar, Iolanda; Garcia, Rosa; Soria, Vincente; Campos, Agustin

CS Dep. quimica Fisica and Inst. Ciencies Materials (ICMUV), Univ.
Valencia, Valencia, 46100, Spain
SO Polymer (1997), 38(14), 3553-3560
CODEN: POLMAG; ISSN: 0032-3861
PB Elsevier
DT Journal
LA English

L1 ANSWER 10 OF 36 CAPLUS COPYRIGHT 1998 ACS
AN 1997:429964 CAPLUS
DN 127:136283
TI Macromolecules in ordered media. 4. Poly(2-vinyl pyridine)-liposome association induced by electrostatic interactions
AU Porcar, Iolanda; Garcia, Rosa; Soria, Vincente; Campos, Agustin
CS Dep. Quimica Fisica and Inst. Ciencies Materials (ICMUV), Univ.
Valencia, Valencia, 46100, Spain
SO Polymer (1997), 38(14), 3545-3552
CODEN: POLMAG; ISSN: 0032-3861
PB Elsevier
DT Journal
LA English

L1 ANSWER 11 OF 36 CAPLUS COPYRIGHT 1998 ACS
AN 1997:85497 CAPLUS
DN 126:135617
TI Method of preparing gas and gaseous precursor-filled microspheres
IN Unger, Evan C.; Fritz, Thomas A.; Matsunaga, Terry; Ramaswami, Varadarajan; Yellowhair, David; Wu, Guanli
PA Imarx Pharmaceutical Corp., USA
SO U.S., 42 pp. Cont.-in-part of U.S. Ser. No. 160,232, abandoned.
CODEN: USXXAM
PI US 5585112 A 19961217
AI US 93-159687 19931130
PRAI US 89-455707 19891222
US 90-569828 19900820
US 90-569828 19900820
US 91-717084 19910618
US 91-716899 19910618
US 93-76239 19930611
US 93-160232 19931130
US 93-159674 19931130
DT Patent
LA English

L1 ANSWER 12 OF 36 CAPLUS COPYRIGHT 1998 ACS
AN 1996:714390 CAPLUS
DN 126:11489
TI Kinetic stability of liposomes.
AU Grohmann, Ferenc Levente; Csempesz, Ferenc; Szogyi, Maria
CS Eotvos Lorand Tudomanyegyetem, Kolloidkemiai es Kolloidtechnologiai

Tanszek, Budapest, H-1117, Hung.
SO Acta Pharm. Hung. (1996), 66(5), 197-202
CODEN: APHGAO; ISSN: 0001-6659
PB Ifjusagi Lap- es Konyvkiado Vallalat
DT Journal
LA Hungarian

L1 ANSWER 13 OF 36 CAPLUS COPYRIGHT 1998 ACS
AN 1996:708315 CAPLUS
DN 125:339057
TI Pharmaceutical liposomes for use in diagnostic applications comprising lipids and stabilizing materials
IN Unger, Evan C.
PA Imarx Pharmaceutical Corp., USA
SO PCT Int. Appl., 51 pp.
CODEN: PIXXD2
PI WO 9631196 A1 19961010
DS W: AU, BR, CA, CN, JP, MX, RU
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
AI WO 96-US4208 19960327
PRAI US 95-417238 19950405
DT Patent
LA English

L1 ANSWER 14 OF 36 CAPLUS COPYRIGHT 1998 ACS
AN 1996:599060 CAPLUS
DN 125:214678
TI Liposome-enhanced immunoaggregation assay and test device
IN Durst, Richard A.; Roberts, Matthew A.
PA Cornell Research Foundation, Inc., USA
SO PCT Int. Appl., 118 pp.
CODEN: PIXXD2
PI WO 9624062 A1 19960808
DS W: AU, CA, JP
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
AI WO 96-US1617 19960129
PRAI US 95-382482 19950201
DT Patent
LA English

L1 ANSWER 15 OF 36 CAPLUS COPYRIGHT 1998 ACS
AN 1996:522069 CAPLUS
DN 125:204402
TI Improved stability of doxorubicin-loaded liposomes by polymer coating
AU Takeuchi, H.; Toyoda, T.; Toyobuku, H.; Yamamoto, H.; Hino, T.; Kawashima, Y.
CS Gifu Pharmaceutical University, Gifu, 502, Japan
SO Proc. Int. Symp. Controlled Release Bioact. Mater. (1996), 23rd, 409-410
CODEN: PCRMEY; ISSN: 1022-0178
DT Journal

LA English

L1 ANSWER 16 OF 36 CAPLUS COPYRIGHT 1998 ACS
AN 1995:875773 CAPLUS
DN 123:333253
TI Synthetic polycations on the surface of negatively charged liposomes
AU Yaroslavov, A. A.; Kul'kov, V. Ye.; Efimova, A. A.; Ignatiev, M. O.
CS Division of Polymer Sciences, Department of Chemistry, Moscow State University, Leninskie Gory, Moscow, V-234, Russia
SO Thin Solid Films (1995), 265(1-2), 66-70
CODEN: THSFAP; ISSN: 0040-6090
DT Journal
LA English

L1 ANSWER 17 OF 36 CAPLUS COPYRIGHT 1998 ACS
AN 1995:654525 CAPLUS
DN 123:34166
TI Macromolecules in ordered media. II. A fluorescence study of the polymer-liposome association
AU Porcar, Iolanda; Gomez, Clara M.; Codoner, Armando; Soria, Vicente; Campos, Agustin
CS Dept. Quim. Fisica, Univ. Valencia, Burjassot, E-46100, Spain
SO Macromol. Symp. (1995), 94(Polymer Spectroscopy), 171-80
CODEN: MSYMEC; ISSN: 1022-1360
DT Journal
LA English

L1 ANSWER 18 OF 36 CAPLUS COPYRIGHT 1998 ACS
AN 1995:630127 CAPLUS
DN 123:152592
TI Surfactant, and emulsion cosmetic and liposome each containing the same
IN Ikemoto, Takeshi; Minamino, Hiromi; Sumida, Yasushi; Inoue, Yoh-ichi
PA Japan
SO PCT Int. Appl., 46 pp.
CODEN: PIXXD2
PI WO 9509692 A1 19950413
DS W: US
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
AI WO 94-JP874 19940531
PRAI JP 93-277653 19931007
DT Patent
LA Japanese
OS MARPAT 123:152592

L1 ANSWER 19 OF 36 CAPLUS COPYRIGHT 1998 ACS
AN 1995:437321 CAPLUS
DN 122:196759
TI Mucoadhesion of polymer-coated liposomes to rat intestine in vitro

AU Takeuchi, Hirofumi; Yamamoto, Hiromitsu; Niwa, Toshiyuki; Hino,
Tomoaki; Kawashima, Yoshiaki
CS Gifu Pharmaceutical University, Gifu, 502, Japan
SO Chem. Pharm. Bull. (1994), 42(9), 1954-6
CODEN: CPBTAL; ISSN: 0009-2363
DT Journal
LA English

L1 ANSWER 20 OF 36 CAPLUS COPYRIGHT 1998 ACS
AN 1995:418734 CAPLUS
DN 122:222625
TI Physicochemical characteristics of the interaction of liquid-crystal
state liposome containing oleic acid and biomembrane
AU Zhang Jing; Sun Run-Guang
CS Experimental Centre, Shaanxi Normal University, Xi'an, 710062, Peop.
Rep. China
SO Wuli Xuebao (1994), 43(9), 1495-501
CODEN: WLHPAR; ISSN: 1000-3290
DT Journal
LA Chinese

L1 ANSWER 21 OF 36 CAPLUS COPYRIGHT 1998 ACS
AN 1995:309106 CAPLUS
DN 122:76040
TI Liposomes incorporating density media
IN Hasskamp, Joanne Haller
PA Becton Dickinson and Co., USA
SO PCT Int. Appl., 19 pp.
CODEN: PIXXD2
PI WO 9426299 A1 19941124
DS W: AU, CA, JP
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
AI WO 94-US5188 19940510
PRAI US 93-61646 19930513
DT Patent
LA English

L1 ANSWER 22 OF 36 CAPLUS COPYRIGHT 1998 ACS
AN 1994:686475 CAPLUS
DN 121:286475
TI Amphiphilic vinyl polymers effectively prolong liposome circulation
time in vivo
AU Torchilin, Vladimir P.; Shtilman, Mikhail I.; Trubetskoy, Vladimir
S.; Whiteman, Kathleen; Milstein, Alexander M.
CS Center for Imaging and Pharmaceutical Research, Massachusetts
General Hospital-East, 149 13th Street, Charlestown, MA, 02129, USA
SO Biochim. Biophys. Acta (1994), 1195(1), 181-4
CODEN: BBACAQ; ISSN: 0006-3002
DT Journal
LA English

L1 ANSWER 23 OF 36 CAPLUS COPYRIGHT 1998 ACS
AN 1992:639655 CAPLUS
DN 117:239655
TI Poly(4-vinylpyridine)-coated liposomes: stability studies and release of acetylsalicylic acid (ASA)
AU Dong, C.; Rogers, J. A.
CS Fac. Pharm. Pharm. Sci., Univ. Alberta, Edmonton, AB, T6G 2N8, Can.
SO J. Microencapsulation (1992), 9(4), 437-48
CODEN: JOMIEF; ISSN: 0265-2048
DT Journal
LA English

L1 ANSWER 24 OF 36 CAPLUS COPYRIGHT 1998 ACS
AN 1992:518349 CAPLUS
DN 117:118349
TI In vitro stability of liposomes in the presence of polymers, trehalose and sodium taurocholate
AU Assadullahi, T. P.; Hamid, K.; Hider, R. C.
CS Dep. Pharm., Kings Coll. Chelsea, London, SW3 6LX, UK
SO J. Microencapsulation (1992), 9(3), 317-27
CODEN: JOMIEF; ISSN: 0265-2048
DT Journal
LA English

L1 ANSWER 25 OF 36 CAPLUS COPYRIGHT 1998 ACS
AN 1992:497214 CAPLUS
DN 117:97214
TI Lyophilization and size control of liposomes entrapping alkaline phosphatase prepared by freeze/thawing method. The effect of additives: sugar, amino acid, protein and water-soluble polymer
AU Kawashima, Y.; Hino, T.; Takeuchi, H.; Niwa, T.; Matsui, K.
CS Gifu Pharm. Univ., Gifu, 502, Japan
SO S.T.P. Pharma Sci. (1992), 2(3), 270-8
CODEN: STSSE5
DT Journal
LA English

L1 ANSWER 26 OF 36 CAPLUS COPYRIGHT 1998 ACS
AN 1990:587630 CAPLUS
DN 113:187630
TI Water-soluble PEG and other polymers in liposome immunoassay to shorten the immunoreaction time
IN Iwase, Noboru; Umeda, Mamoru; Shibata, Hideaki
PA Nissui Seiyaku Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 9 pp.
CODEN: JKXXAF
PI JP 02087064 A2 19900327 Heisei
AI JP 88-240442 19880926
DT Patent
LA Japanese

L1 ANSWER 27 OF 36 CAPLUS COPYRIGHT 1998 ACS

AN 1990:240531 CAPLUS
DN 112:240531
TI . System for delayed and pulsed release of biologically active substances
IN Wheatley, Margaret A.; Langer, Robert S.; Eisen, Herman N.
PA Massachusetts Institute of Technology, USA
SO U.S., 11 pp. Cont. of U.S. Ser. No. 727,802, abandoned.
CODEN: USXXAM
PI US 4900556 A 19900213
AI US 88-161198 19880223
PRAI US 85-727802 19850426
DT Patent
LA English

L1 ANSWER 28 OF 36 CAPLUS COPYRIGHT 1998 ACS
AN 1989:141567 CAPLUS
DN 110:141567
TI Liposome composition for treating dry eye
IN Guo, Luke S. S.
PA Liposome Technology, Inc., USA
SO PCT Int. Appl., 36 pp.
CODEN: PIXXD2
PI WO 8803018 A1 19880505
DS W: AU, DK, JP
RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE
AI WO 87-US2707 19871020
PRAI US 86-910008 19861021
DT Patent
LA English

L1 ANSWER 29 OF 36 CAPLUS COPYRIGHT 1998 ACS
AN 1987:593454 CAPLUS
DN 107:193454
TI Measurement of surface charge on various liposomes
AU Noda, Yasuko
CS Okayama Univ., Okayama, 700, Japan
SO Bunseki Kagaku (1987), 36(7), 403-6
CODEN: BNSKAK; ISSN: 0525-1931
DT Journal
LA Japanese

L1 ANSWER 30 OF 36 CAPLUS COPYRIGHT 1998 ACS
AN 1987:38358 CAPLUS
DN 106:38358
TI Critical parameters in freezing of liposomes
AU Fransen, G. J.; Salemink, P. J. M.; Crommelin, D. J. A.
CS Subfac. Pharm., State Univ. Utrecht, Utrecht, Neth.
SO Int. J. Pharm. (1986), 33(1-3), 27-35
CODEN: IJPHDE; ISSN: 0378-5173
DT Journal
LA English

L1 ANSWER 31 OF 36 CAPLUS COPYRIGHT 1998 ACS
AN 1984:497665 CAPLUS
DN 101:97665
TI Triiodothyroacetic acid and glycosaminoglycan compositions for the

treatment of cellulitis
IN Curri, Sergio
PA Berema S. A., Switz.
SO Patentschrift (Switz.), 4 pp.
CODEN: SWXXAS
PI CH 642851 A 19840515
AI CH 80-1168 19800213
DT Patent
LA French

L1 ANSWER 32 OF 36 CAPLUS COPYRIGHT 1998 ACS
AN 1983:95577 CAPLUS
DN 98:95577
TI Experimental study on enhancing the stability of liposomes with
mannitol-PVS
AU Chen, Yuanqing; Jiang, Huiqiu; Zhang, Jinde; Yan, Genbao; Ma, Jiqing; Shen, Defen; Gu, Jianren
CS Shanghai Cancer Inst., Shanghai, Peop. Rep. China
SO Yaoxue Xuebao (1982), 17(11), 847-53
CODEN: YHHPAL; ISSN: 0513-4870
DT Journal
LA Chinese

L1 ANSWER 33 OF 36 CAPLUS COPYRIGHT 1998 ACS
AN 1981:197479 CAPLUS
DN 94:197479
TI Uptake by rat peritoneal macrophages of 125I-labeled poly(vinylpyrrolidone) entrapped within liposomes
AU Pratten, Margaret K.; Millard, Peter C.; Lloyd, John B.
CS Dep. Biol. Sci., Univ. Keele, Keele/Staffs., ST5 5BG, Engl.
SO Biosci. Rep. (1981), 1(2), 125-33
CODEN: BRPTDT
DT Journal
LA English

L1 ANSWER 34 OF 36 CAPLUS COPYRIGHT 1998 ACS
AN 1981:118441 CAPLUS
DN 94:118441
TI The uptake of distearoylphosphatidylcholine/cholesterol liposomes by
rat intestinal sacs in vitro
AU Rowland, Richard N.; Woodley, John F.
CS Dep. Biol. Sci., Univ. Keele, Keele/Staffordshire, ST5 5BG, Engl.
SO Biochim. Biophys. Acta (1981), 673(2), 217-23
CODEN: BBACAQ; ISSN: 0006-3002
DT Journal
LA English

L1 ANSWER 35 OF 36 CAPLUS COPYRIGHT 1998 ACS
AN 1979:67014 CAPLUS
DN 90:67014
TI The uptake of liposome-entrapped iodine-125-labeled poly(vinylpyrrolidone) by rat jejunum in vitro
AU Bridges, Janine F.; Millard, Peter C.; Woodley, John F.
CS Dep. Biol. Sci., Univ. Keele, Keele/Staffordshire, Engl.

SO Biochim. Biophys. Acta (1978), 544(2), 448-51
CODEN: BBACAQ; ISSN: 0006-3002
DT Journal
LA English

L1 ANSWER 36 OF 36 CAPLUS COPYRIGHT 1998 ACS
AN 1976:173574 CAPLUS
DN 84:173574
TI Penetration of target areas in the rat by liposome-associated bleomycin, glucose oxidase and insulin
AU Dapergolas, Gerry; Neerunjun, E. Diane; Gregoriadis, Gregory
CS Div. Clin. Invest., Clin. Res. Cent., Harrow/Middx, Engl.
SO FEBS Lett. (1976), 63(2), 235-9
CODEN: FEBLAL
DT Journal
LA English

=> d 23 28 bib ab

L1 ANSWER 23 OF 36 CAPLUS COPYRIGHT 1998 ACS
AN 1992:639655 CAPLUS
DN 117:239655
TI Poly(4-vinylpyridine)-coated liposomes: stability studies and release of acetylsalicylic acid (ASA)
AU Dong, C.; Rogers, J. A.
CS Fac. Pharm. Pharm. Sci., Univ. Alberta, Edmonton, AB, T6G 2N8, Can.
SO J. Microencapsulation (1992), 9(4), 437-48
CODEN: JOMIEF; ISSN: 0265-2048
DT Journal
LA English
AB Liposomes of dimyristoylphosphatidylcholine (DMPC) and dicetylphosphate (DCP) reacted with 4-vinylpyridine (4-VP) to form a salt and, subsequently, autopolymd. to form poly(4-vinylpyridine) [poly(4-VP)]-coated liposomes. The conditions for optimization of polymer coating have been detd.; also, the effects of polymer coating on liposome stability, the encapsulation of ASA and its release kinetics have been measured. The coating efficiency was max. at a DMPC/DCP 1:1 mol ratio, at pH 4.0 in acetate buffer, and a polymn. time of 40 min. The polymer-coated liposomes were stable in 2 mM sodium cholate and 4% isopropanol solns., as detd. from turbidity measurements, vs. a 20-25% decrease in stability of uncoated liposomes. The encapsulation efficiency of ASA reached a max. of 9% at DMPC/DCP 1:1 mol ratio. The release of ASA at 37.degree., pH 7.0 was characterized by an initial fast release (85 and 63% in 20 min from uncoated and polymer-coated liposomes, resp.)

followed by a slow, const. release rate up to 140 min. Thus, autopolymn. of a polymerizable monomer at liposome surfaces represents a potentially feasible stabilization approach for liposomes exposed to sodium cholate solns. with greater retention of solute than uncoated liposomes.

L1 ANSWER 28 OF 36 CAPLUS COPYRIGHT 1998 ACS
AN 1989:141567 CAPLUS
DN 110:141567
TI Liposome composition for treating dry eye
IN Guo, Luke S. S.
PA Liposome Technology, Inc., USA
SO PCT Int. Appl., 36 pp.
CODEN: PIXXD2
PI WO 8803018 A1 19880505
DS W: AU, DK, JP
RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE
AI WO 87-US2707 19871020
PRAI US 86-910008 19861021
DT Patent
LA English
AB Storage-stable liposome compns. for treatment of dry eye contain liposomes composed of 70-85 mol% hydrogenated phosphatidylcholine, and 15-30 mol% benzyldimethylstearylammonium chloride (I). Small unilamellar vesicles are prepd. by homogenation of multilamellar vesicles prepd. from 80 mol% egg phosphatidylcholine and 20 mol% I in saline-buffer. One hour after administration, 20% of these liposomes were retained on rabbit eyes, compared to 7% retention of liposomes contg. egg phosphatidylcholine only. Liposome formulations contg. 0.01 and 0.05% I were nonirritating to rabbits eyes following a single topical application.

=> file wpids

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|---|---|---|
| FULL ESTIMATED COST | 38.54 | 38.69 |

| DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) | SINCE FILE ENTRY | TOTAL SESSION |
|---|---|---|
| CA SUBSCRIBER PRICE | -1.03 | -1.03 |

FILE 'WPIDS' ENTERED AT 08:01:23 ON 17 NOV 1998

```
COPYRIGHT (C) 1998 DERWENT INFORMATION LTD

FILE LAST UPDATED: 11 NOV 1998              <19981111/UP>
>>>UPDATE WEEKS:
MOST RECENT DERWENT WEEK            199845   <199845/DW>
DERWENT WEEK FOR CHEMICAL CODING:   199840
DERWENT WEEK FOR POLYMER INDEXING:  199842
DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

>>> D COST AND SET NOTICE DO NOT REFLECT SUBSCRIBER DISCOUNTS -
                                        SEE HELP COST FOR DETAILS <<<
>>> DELIMITED FORMAT DALL NOW AVAILABLE <<<

=> s liposome?(5a)(polylact? or polyglycol? or polyvinyl?)

          2609 LIPOSOME?
          1651 POLYLACT?
          4531 POLYGLYCOL?
         98553 POLYVINYL?
L2           2 LIPOSOME?(5A)(POLYLACT? OR POLYGLYCOL? OR
POLYVINYL?)

=> d 1-2


L2   ANSWER 1 OF 2  WPIDS   COPYRIGHT 1998 DERWENT INFORMATION LTD

AN   94-264036 [32]   WPIDS
DNC  C94-120835
TI   New immunogenic lysergic cpd.-protein conjugates and corresp.
     antibodies - used as vaccine for treating or presenting fescue
     toxicosis in herbivores.
DC   B04 C06 D16
IN   DAWE, D L; HILL, N S; STUEDEMANN, J A; THOMPSON, F N;
STUDEMANN, J A
PA   (UYGE-N) UNIV GEORGIA RES FOUND INC; (USDA) US SEC OF AGRIC
CYC  26
PI   WO 9417104  A1 940804 (9432)* EN   45 pp    C07K015-00
        RW: AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE
         W: AU BR CA JP KP NZ RU UA US
     AU 9461645  A  940815 (9444)                C07K015-00
     EP 683793   A1 951129 (9601)  EN            C07K015-00
         R: AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE
     BR 9405664  A  960430 (9624)                C07K004-10
     EP 683793   A4 970409 (9735)                C07K015-00
     US 5718900  A  980217 (9814)        9 pp    A61K039-385
     AU 692435   B  980611 (9834)                C07K015-12
     NZ 262248   A  980924 (9845)                C07D471-02
ADT  WO 9417104 A1 WO 94-US812 940121; AU 9461645 A AU 94-61645
940121;
     EP 683793 A1 EP 94-908622 940121, WO 94-US812 940121; BR
9405664 A
     BR 94-5664 940121, WO 94-US812 940121; EP 683793 A4 EP
94-908622
     ; US 5718900 A Cont of US 93-7141 930121, US 94-326734
941020; AU
     692435 B AU 94-61645 940121; NZ 262248 A NZ 94-262248 940121,
WO
```

94-US812 940121
FDT AU 9461645 A Based on WO 9417104; EP 683793 A1 Based on WO 9417104;
BR 9405664 A Based on WO 9417104; AU 692435 B Previous Publ. AU
9461645, Based on WO 9417104; NZ 262248 A Based on WO 9417104
PRAI US 93-7141 930121; US 94-326734 941020
IC ICM A61K039-385; C07D471-02; C07K004-10; C07K015-00; C07K015-12
ICS A61K031-48; A61K037-02; A61K038-03; A61K039-00; A61K039-395;
C07K004-12; C07K013-00; C07K101-00; C12N005-12

L2 ANSWER 2 OF 2 WPIDS COPYRIGHT 1998 DERWENT INFORMATION LTD

AN 91-368973 [50] WPIDS
DNN N91-282498
TI Medical device polymer - has tissue exposed surface constructed to
release agent that inhibits adverse reaction to pressure of device.
DC P32 P34
IN HELMUS, M N; RALEIGH, C L; TOLKOFF, M J; TOLKOFF, M
PA (HARB-N) HARBOR MED DEVICES; (HARB-N) HARBOR MEDICAL DEVICES INC
CYC 2
PI WO 9117724 A 911128 (9150)*
AU 9179980 A 911210 (9212)
US 5447724 A 950905 (9541) 15 pp A61F002-04
US 5569463 A 961029 (9649) 15 pp A61F002-04
ADT US 5447724 A Cont of US 90-525339 900517, US 93-152876 931115; US
5569463 A Cont of US 90-525339 900517, Div ex US 93-152876 931115,
US 95-479513 950607
FDT US 5569463 A Div ex US 5447724
PRAI US 90-525339 900517; US 93-152876 931115; US 95-479513 950607
IC A61F002-48
ICM A61F002-04
ICS A01N001-02; A61F002-48; A61M005-32

=> d 1-2 bib ab

L2 ANSWER 1 OF 2 WPIDS COPYRIGHT 1998 DERWENT INFORMATION LTD

AN 94-264036 [32] WPIDS
DNC C94-120835
TI New immunogenic lysergic cpd.-protein conjugates and corresp. antibodies - used as vaccine for treating or presenting fescue toxicosis in herbivores.
DC B04 C06 D16
IN DAWE, D L; HILL, N S; STUEDEMANN, J A; THOMPSON, F N; STUDEMANN, J A
PA (UYGE-N) UNIV GEORGIA RES FOUND INC; (USDA) US SEC OF AGRIC
CYC 26

PI WO 9417104 A1 940804 (9432)* EN 45 pp
RW: AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE
W: AU BR CA JP KP NZ RU UA US
AU 9461645 A 940815 (9444)
EP 683793 A1 951129 (9601) EN
R: AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE
BR 9405664 A 960430 (9624)
EP 683793 A4 970409 (9735)
US 5718900 A 980217 (9814) 9 pp
AU 692435 B 980611 (9834)
NZ 262248 A 980924 (9845)
ADT WO 9417104 A1 WO 94-US812 940121; AU 9461645 A AU 94-61645 940121;
EP 683793 A1 EP 94-908622 940121, WO 94-US812 940121; BR 9405664 A
BR 94-5664 940121, WO 94-US812 940121; EP 683793 A4 EP 94-908622
; US 5718900 A Cont of US 93-7141 930121, US 94-326734 941020; AU
692435 B AU 94-61645 940121; NZ 262248 A NZ 94-262248 940121, WO
94-US812 940121
FDT AU 9461645 A Based on WO 9417104; EP 683793 A1 Based on WO 9417104;
BR 9405664 A Based on WO 9417104; AU 692435 B Previous Publ. AU
9461645, Based on WO 9417104; NZ 262248 A Based on WO 9417104
PRAI US 93-7141 930121; US 94-326734 941020
AB WO 9417104 A UPAB: 940928
Immunogenic lysergic cpd. -protein conjugates of formula (I) are
new. Where, X = H or Me; R1 = suitable functional gp. of the
lysergic ring; R2 = immunogenic protein; and Y = linking bridge.
Also claimed are: (a) purified antibodies (II) reactive with
the lysergin ring of (I), where (II) are pref. monoclonal (II') (b)
(II')-producing hybridoma cell lines, specifically cell line
15F3.E5; and (c) antibodies (II'') which are anti-idiotypes of
(II').
USE - (I) and (II') are used (claimed) for preventing or
treating fescue toxicosis (FT) in, herbivores (II'') is also used
for preventing FT. Specifically a vaccine contg. an immunogenic amt.
of lysergol-glutarate-human serum albumin conjugate (Ia) is used to
prevent FT. FT is caused by grazing tall fescue (Festuca
arundinacea) infected with the fungus Acremonium coenophialum, which
produces toxic alkaloids.
Claimed doses are 1-40 (esp.20)mg. of (I) (including (Ia) as
vaccine); or 0.1-1.3 (pref. 0.5) mg/kg. of (II') daily. (I) is pref.
used in a sustained release prepn., specifically microsphere

polymers, **liposomes, polylactic** acid or
microcapsules. Vaccines may be administered im.m. or s.c.
Dwg.0/3

L2 ANSWER 2 OF 2 WPIDS COPYRIGHT 1998 DERWENT INFORMATION LTD

AN 91-368973 [50] WPIDS
DNN N91-282498
TI Medical device polymer - has tissue exposed surface constructed to
release agent that inhibits adverse reaction to pressure of device.
DC P32 P34
IN HELMUS, M N; RALEIGH, C L; TOLKOFF, M J; TOLKOFF, M
PA (HARB-N) HARBOR MED DEVICES; (HARB-N) HARBOR MEDICAL DEVICES INC
CYC 2
PI WO 9117724 A 911128 (9150)*
AU 9179980 A 911210 (9212)
US 5447724 A 950905 (9541) 15 pp
US 5569463 A 961029 (9649) 15 pp
ADT US 5447724 A Cont of US 90-525339 900517, US 93-152876 931115; US
5569463 A Cont of US 90-525339 900517, Div ex US 93-152876 931115,
US 95-479513 950607
FDT US 5569463 A Div ex US 5447724
PRAI US 90-525339 900517; US 93-152876 931115; US 95-479513 950607
AB WO 9117724 A UPAB: 951019
The medical device has a tissue exposed part and it is constructed
to release an agent that inhibits adverse reaction to the presence
of the device. This is a polymer surface layer overlying a polymer
defining a reservoir. This reservoir has the agent so that it is
allowed free outward release.
The overlying layer defines a metering outward passage. This
enables polonged release of the agent over a period of time.
ADVANTAGE - Helps prevent rejection of device by body. @(43pp
Dwg.No. 1/5)@

=> log y

COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 14.20 52.89

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL

ENTRY

SESSION
CA SUBSCRIBER PRICE 0.00
-1.03

STN INTERNATIONAL LOGOFF AT 08:02:39 ON 17 NOV 1998

```
=> s liposome?(5a)(aminoglycoside? or gentamycin)

          7541 LIPOSOME?
          2054 AMINOGLYCOSIDE?
          1962 GENTAMYCIN
L1          25 LIPOSOME?(5A)(AMINOGLYCOSIDE? OR GENTAMYCIN)

=> d 1-25
```

1. 5,820,848, Oct. 13, 1998, Methods of preparing interdigitation-fusion liposomes and gels which encapsulate a bioactive agent; Lawrence T. Boni, et al., 424/9.4; 264/4.1; 424/1.21, 9.321, 450; 436/829 [IMAGE AVAILABLE]

2. 5,773,221, Jun. 30, 1998, Method of recovering a biological molecule from a recombinant microorganism; Peter S. Carlson, et al., 435/6, 490 [IMAGE AVAILABLE]

3. 5,759,571, Jun. 2, 1998, Antibiotic formulation and use for drug resistant infections; Evan M. Hersch, et al., 424/450 [IMAGE AVAILABLE]

4. 5,756,121, May 26, 1998, Antibiotic formulation and use for drug resistant infections; Kevin R. Bracken, 424/450; 264/4.1, 4.3 [IMAGE AVAILABLE]

5. 5,756,120, May 26, 1998, Antibiotic formulation and use for drug resistant infections; Evan M. Hersch, et al., 424/450 [IMAGE AVAILABLE]

6. 5,662,929, Sep. 2, 1997, Therapeutic liposomal formulation; Jacqueline Lagace , et al., 424/450; 514/36, 37, 38, 39, 40 [IMAGE AVAILABLE]

7. 5,643,599, Jul. 1, 1997, Intracellular delivery of macromolecules; Kyung-Dall Lee, et al., 424/450; 436/829 [IMAGE AVAILABLE]

8. 5,578,320, Nov. 26, 1996, Method of dehydrating liposomes using protective sugars; Andrew S. Janoff, et al., 424/450; 264/4.1, 4.3, 4.6

[IMAGE AVAILABLE]

9. RE 35,338, Sep. 24, 1996, Sustained release delivery of water soluble
bio-molecules and drugs using phosphokipid-coated microcrystals, microdroplets and high-concentration lipsomes; Duncan H. Haynes, 424/450,
184.1, 204.1, 234.1, 405, 408, 409, 417, 420, 422, 646, 647 [IMAGE AVAILABLE]

10. 5,540,936, Jul. 30, 1996, Method of producing liposomes; Royden M.
Coe, et al., 424/450; 264/4.1, 4.3; 428/402.2 [IMAGE AVAILABLE]

11. 5,527,528, Jun. 18, 1996, Solid-tumor treatment method; Theresa M.
Allen, et al., 424/178.1, 181.1, 450, 812 [IMAGE AVAILABLE]

12. 5,409,704, Apr. 25, 1995, **Liposomes** comprising **aminoglycoside** phosphates and methods of production and use; Marcel B. Bally, et al., 424/450; 264/4.1, 4.3; 428/402.2; 514/37, 78, 912, 913,
914 [IMAGE AVAILABLE]

13. 5,366,958, Nov. 22, 1994, Localized delivery using fibronectin conjugates; Alan L. Weiner, et al., 514/2; 424/450; 530/380, 810, 812
[IMAGE AVAILABLE]

14. 5,288,499, Feb. 22, 1994, Sterodial liposomes; Andrew S. Janoff, et
al., 424/450; 264/4.1, 4.6; 424/1.21, 9.4; 428/402.2; 436/829; 514/78,
167, 887, 967 [IMAGE AVAILABLE]

15. 5,246,707, Sep. 21, 1993, Sustained release delivery of water-soluble bio-molecules and drugs using phospholipid-coated microcrystals, microdroplets and high-concentration liposomes; Duncan H.
Haynes, 424/450, 196.11, 197.11, 283.1, 405, 408, 409, 420 [IMAGE AVAILABLE]

16. 5,231,112, Jul. 27, 1993, Compositions containing tris salt of cholesterol hemisuccinate and antifungal; Andrew S. Janoff, et al., 514/401; 424/DIG.15; 514/887, 967 [IMAGE AVAILABLE]

17. 5,213,804, May 25, 1993, Solid tumor treatment method and composition; Francis J. Martin, et al., 424/450, 78.31, 426 [IMAGE AVAILABLE]

18. 5,211,955, May 18, 1993, Pharmaceutical composition containing a
hydrophilic active compound, treated with an organic acid and encapsulated in a liposome; Franz Legros, et al., 424/450; 264/4.1; 424/427; 514/39, 912 [IMAGE AVAILABLE]

19. 5,059,591, Oct. 22, 1991, Drug preparations of reduced toxicity;

Andrew S. Janoff, et al., 514/31; 424/116, 450; 514/78, 766 [IMAGE AVAILABLE]

20. 5,000,958, Mar. 19, 1991, Enhancement of pharmaceutical activity;
Michael W. Fountain, et al., 424/450, 417 [IMAGE AVAILABLE]

21. 4,981,692, Jan. 1, 1991, Therapeutic treatment by intramammary infusion; Mircea Popescu, et al., 424/422, 450; 428/402.2; 514/37, 885
[IMAGE AVAILABLE]

22. 4,952,405, Aug. 28, 1990, Method of treating M. avium infection;
Annie Yau-Young, 424/423, 450; 428/402.2; 514/37, 922 [IMAGE AVAILABLE]

23. 4,897,384, Jan. 30, 1990, Drug preparations of reduced toxicity;
Andrew S. Janoff, et al., 514/34; 524/78; 536/6, 13, 16.8, 17.2, 17.9
[IMAGE AVAILABLE]

24. 4,891,208, Jan. 2, 1990, Steroidal liposomes; Andrew S. Janoff, et
al., 424/1.21; 264/4.1, 4.6; 424/9.4, 9.6, 450; 428/402.2; 436/829; 514/3, 78, 167, 396, 885, 887, 967; 604/891.1 [IMAGE AVAILABLE]

25. 4,721,612, Jan. 26, 1988, Steroidal liposomes; Andrew S. Janoff, et
al., 424/1.21; 264/4.1, 4.6; 424/9.4, 9.6, 450; 428/402.2; 436/52, 829;
514/78, 167, 887, 967 [IMAGE AVAILABLE]

=> d 22 kwic

US PAT NO: 4,952,405 [IMAGE AVAILABLE] L1: 22 of 25

DETDESC:

DETD(67)

As . . . gentamicin-liposomes after I.V. injection is similar to that
of amikacin liposomes. To examine the difference in drug clearance between free **aminoglycoside** and an **aminoglycoside-liposome** composition, free amikacin and amikacin-liposomes were administered to
groups of mice, as above, and the amount of drug excreted by. . .

DETDESC:

DETD(69)

Efficacy of **Aminoglycoside Liposomes** Against MAC Infected "Beige"

=> d 25 kwic

US PAT NO: 4,721,612 [IMAGE AVAILABLE] L1: 25 of 25

SUMMARY:

BSUM(37)
9. Example: The Use of Cholesterol Hemisuccinate **Liposomes** to Determine **Aminoglycoside** Concentration in Serum

DETDESC:

DETD(120)

9. EXAMPLE: THE USE OF CHOLESTEROL HEMISUCCINATE **LIPOSOMES** TO DETERMINE **AMINOGLYCOSIDE** CONCENTRATION IN SERUM

=> s l1 and gentamycin

1962 GENTAMYCIN
L2 12 L1 AND GENTAMYCIN

=> d 1-12

1. 5,643,599, Jul. 1, 1997, Intracellular delivery of macromolecules; Kyung-Dall Lee, et al., 424/450; 436/829 [IMAGE AVAILABLE]

2. RE 35,338, Sep. 24, 1996, Sustained release delivery of water soluble bio-molecules and drugs using phosphokipid-coated microcrystals, microdroplets and high-concentration lipsomes; Duncan H. Haynes, 424/450, 184.1, 204.1, 234.1, 405, 408, 409, 417, 420, 422, 646, 647 [IMAGE AVAILABLE]

3. 5,288,499, Feb. 22, 1994, Sterodial liposomes; Andrew S. Janoff, et al., 424/450; 264/4.1, 4.6; 424/1.21, 9.4; 428/402.2; 436/829; 514/78, 167, 887, 967 [IMAGE AVAILABLE]

4. 5,246,707, Sep. 21, 1993, Sustained release delivery of water-soluble bio-molecules and drugs using phospholipid-coated microcrystals, microdroplets and high-concentration liposomes; Duncan H. Haynes, 424/450, 196.11, 197.11, 283.1, 405, 408, 409, 420 [IMAGE AVAILABLE]

5. 5,231,112, Jul. 27, 1993, Compositions containing tris salt of cholesterol hemisuccinate and antifungal; Andrew S. Janoff, et al., 514/401; 424/DIG.15; 514/887, 967 [IMAGE AVAILABLE]

6. 5,211,955, May 18, 1993, Pharmaceutical composition containing a
hydrophilic active compound, treated with an organic acid and encapsulated in a liposome; Franz Legros, et al., 424/450; 264/4.1; 424/427; 514/39, 912 [IMAGE AVAILABLE]

7. 5,059,591, Oct. 22, 1991, Drug preparations of reduced toxicity;
Andrew S. Janoff, et al., 514/31; 424/116, 450; 514/78, 766 [IMAGE AVAILABLE]

8. 5,000,958, Mar. 19, 1991, Enhancement of pharmaceutical activity;
Michael W. Fountain, et al., 424/450, 417 [IMAGE AVAILABLE]

9. 4,981,692, Jan. 1, 1991, Therapeutic treatment by intramammary infusion; Mircea Popescu, et al., 424/422, 450; 428/402.2; 514/37, 885
[IMAGE AVAILABLE]

10. 4,897,384, Jan. 30, 1990, Drug preparations of reduced toxicity;
Andrew S. Janoff, et al., 514/34; 524/78; 536/6, 13, 16.8, 17.2, 17.9
[IMAGE AVAILABLE]

11. 4,891,208, Jan. 2, 1990, Steroidal liposomes; Andrew S. Janoff, et
al., 424/1.21; 264/4.1, 4.6; 424/9.4, 9.6, 450; 428/402.2; 436/829; 514/3, 78, 167, 396, 885, 887, 967; 604/891.1 [IMAGE AVAILABLE]

12. 4,721,612, Jan. 26, 1988, Steroidal liposomes; Andrew S. Janoff, et
al., 424/1.21; 264/4.1, 4.6; 424/9.4, 9.6, 450; 428/402.2; 436/52, 829;
514/78, 167, 887, 967 [IMAGE AVAILABLE]

=> d 10 kwic

US PAT NO: 4,897,384 [IMAGE AVAILABLE] L2: 10 of 12

SUMMARY:

BSUM(37)

The aminoglycoside antibiotics (e.g., streptomycin, **gentamycin**, kanamycin, tobramycin, etc.) are used almost exclusively to treat infections caused by bacteria. Their mode of bactericidal action involves
inhibition. . .

SUMMARY:

BSUM(42)

The toxic effect of aminoglycosides such as streptomycin and

**gentamycin** is greater upon the vestibular than auditory component of
the eighth cranial nerve, however, a decrease in hearing occurs in.. . .

SUMMARY:

BSUM(43)

Nephrotoxicity . . . these drugs to cause nephrotoxicity. For this
reason, neomycin, the most nephrotoxic aminoglycoside, is not generally
administered systemically in humans. **Gentamycin** seems to be the most
nephrotoxic of the commonly used drugs.

SUMMARY:

BSUM(46)

These . . . are shared to varying degrees by several other aminoglycoside antibiotics, particularly neomycin and kanamycin, and to a
lesser extent by **gentamycin**, viomycin, paromomycin and tobramycin. Interestingly, the order of increasing ability of the aminoglycosides to
affect acute toxic reactions seems to. . .

SUMMARY:

BSUM(69)

Concurrent . . . which exert a synergistic effect in vitro cannot be
formulated in a single mixture to use in vitro. Mixtures of **gentamycin** and nafcillin, a penicillin, at therapeutically effective
concentrations result in the formation of complexes that precipitate out
of solution and,. . . formation of a precipitate). For example, it is
recommended that the following antibiotics not be mixed with any other
drug: **gentamycin**, kanamycin, lincomycin, cephalothin, and ampicillin
(Davis and Abbitt, 1977, JAVMA 170(2):204-207). Moreover, certain agents
cannot be solubilized in the same. . .

DETDESC:

DETD(10)

Further, . . . will spontaneously form liposomes at excess concentrations in water (above their critical micelle concentrations)

would also be expected to reduce **aminoglycoside** toxicity. Such **aminoglycoside**-containing **liposomes** would allow **aminoglycosides** to be given safely above the LD.sub.10 or LD.sub.50 of the free drug. For example, the LD.sub.50 of streptomycin in. . .

DETDESC:

DETD(11)

In . . . phosphatidylinositol bisphosphate may be especially useful when used at concentrations greater than their critical micelle concentrations; that is, with the **aminoglycoside** antibiotic encapsulated within **liposomes** of these phospholipids. As discussed above, these phospholipids are the putative toxicity receptors for aminoglycosides, and for this reason, they. . .

DETDESC:

DETD(13)

The aminoglycoside antibiotics which may be used in the present invention include but are not limited to: streptomycin, **gentamycin**, tobramycin, amikacin, kanamycin and neomycin.

DETDESC:

DETD(18)

(1) SDS-Polyacrylamide Gel Electrophoresis: Equal volumes of mouse serum were incubated for 0.5 hour and 2 hours with .sup.125 I-**gentamycin** sulfate (.sup.125 I-GS) or with .sup.125 I-**gentamycin**-phosphorylcholine (.sup.125 I-GPC), 1:3 molar ratio, at 1.times.10.sup.5 cpm per sample. Aliquots of the incubated serum samples and aliquots of .sup.125. . .

DETDESC:

DETD(19)

Since . . . C-Blue, this low molecular weight band which is stained by C-Blue and is also radioactively labeled represents the putative .sup.125 I-**gentamycin**-phosphorylcholine complex. Interestingly, the putative complex did not dissociate under the denaturing conditions used in the sample preparation for SDS-PAGE.

DETDESC:
<------User Break------>
u

DETD(56)